Lifeboat Foundation

In America, roughly 40 million Americans have diabetes and about 95% of them have type 2 diabetes. Type 2 diabetes occurs when the body cannot correctly process sugar and fuel cells. More specifically, the body does not produce enough insulin to break down sugar into glucose for the cells to use. In this case, treatment includes insulin shots or a pump in addition to a strict diet excluding sweets or high fat meals. Treatment limitations disrupt patient quality of life. Some researchers have been working on better detection for diabetic retinopathy with artificial intelligence (AI), but research is limited on how to better detect diabetes itself. Thus, many researchers are working to detect diabetes early on and discover better treatments.

Klick labs, located in multiple cities across the world, is trying to detect type 2 diabetes by having a patient speak into a microphone for 10 seconds. Klick labs believes this technology can better detect diabetes and help patients get treatment earlier. The study was published in Mayo Clinic Proceedings: Digital Health, which details how patients spoke for 10 seconds and combined with health data, including age, sex, height, and weight, created an AI model that discerns whether a person has type 2 diabetes or not. After further tests, scientists determined it has 89% and 86% accuracy for women and men, respectively.

In the study, Klick Labs collected voice recordings of 267 people, either non-diabetic or diabetic. The participants were asked to record a phrase into their smartphones six times a day for a total of 2-weeks. Over 18,000 recordings were taken and analyzed to distinguish 14 acoustic features that helped distinguish non-diabetic to type 2 diabetic individuals. The research highlights specific vocal variations in pitch and intensity that could lead to how the medical community screens for early-onset diabetes. A major barrier to early detection includes time, travel, and cost, which many people do not have. Voice diagnosis can help eliminate those barriers and improve detection and treatment in diabetic patients.

Cocaine use continues to be a public health problem, yet despite concerted efforts, no drugs have been approved to resolve cocaine addiction. Research suggests that the attention-deficit/hyperactivity disorder drug methylphenidate (MPH; Ritalin) could serve as a cocaine-replacement therapy, but clinical results have been mixed. Although several labs have produced MPH derivatives for testing, parts of the molecule remained chemically inaccessible. Now, researchers reporting in ACS Central Science have cleared that hurdle.

According to the Centers for Disease Control and Prevention, more than 5 million Americans reported actively using cocaine in 2020, and almost 25,000 Americans died of a cocaine-related overdose in 2021. Although small-molecule drugs have proven effective in treating other drug addictions—for example, methadone as a therapy for heroin abuse—no such medication exists for cocaine abuse.

MPH has been considered a potential treatment because it behaves similarly to the illicit drug, increasing dopamine levels in the brain by blocking dopamine reuptake. Additionally, clinical studies have shown that MPH has a lower risk of abuse than cocaine.

Viruses that infect bacteria – called phages – are abundant in our bodies, and they seem to have beneficial effects when our cells engulf them.

By Kamal Nahas

Bacterial diversity in the gut plays an important role in health. The human microbiome has featured prominently in research, with links being made between it and cancer, personality, memory, and diseases such as diabetes and multiple sclerosis.

While it’s understood that a mother’s microbiome is transferred to their baby at birth and boosted by breastfeeding, what other sources of gut bacteria are there? A new study by researchers at the Graz University of Technology (TU Graz) in Austria has confirmed, for the first time, that one source is fruits and vegetables.

The human gut microbiome has a crucial connection to our health and well-being, but it is a complex entity made up of many different organisms, which all have an effect on one another. The hundreds of different microbial species in the gut metabolize the foods we consume in different ways, and the metabolites that microbes generate are often then consumed by other microbes. It’s been suggested that the more than half of the stuff that is eaten by gut microbes are byproducts of other gut microbes. This interdependence can have profound implications for the gut microbiome, and some species become totally reliant on the presence of others.

Scientists are still learning about the various characteristics of a healthy human gut microbiome, but there are certain species that tend to be present. High diversity in the microbiome is also typically associated with good health. While some microbes can fill in the gaps if other important ones are missing, some species can’t be substituted.

Magnets are magnificent. Made of iron, aluminum, nickel, cobalt, and various other metals, they’re used in compasses for navigation, in medical imaging machines to see inside the human body, in kitchens to keep cabinets and refrigerators closed, in computers to store data and in new high-speed “hyperloop” trains that can travel at speeds of up to 76 miles per hour.

For environmentalists, however, the most exciting use yet for magnets might be a newly discovered application out of Australia’s Royal Melbourne Institute of Technology, otherwise known as RMIT University: Using magnets, researchers there have discovered a novel way of removing harmful microplastics from water.

“[Microplastics] can take up to 450 years to degrade, are not detectable and removable through conventional treatment systems, resulting in millions of tons being released into the sea every year,” co-lead research Nasir Mahmood said in a statement. “This is not only harmful for aquatic life, but also has significant negative impacts on human health.”

A new study shows that cerebrospinal fluid reduces current treatment efficacy in brain cancer and identifies new therapeutic opportunities.

Cerebrospinal fluid, the clear colorless liquid that protects the brain, also may be a factor that makes brain cancers resistant to treatment, Australian researchers led by Associate Professor Cedric Bardy at the South Austraila Health and Medical Research Institute (SAHMRI) and Flinders University reveal in the journal Science Advances.

Reporting how this occurs, the study, titled “Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma,” in Science Advances shows that a decades-old anti-anxiety drug can improve the effectiveness of chemo-radiotherapy towards glioblastoma, or GBM, the most common and lethal brain cancer.

The results of a human study carried out by an international research team have provided valuable new insights into the activity of the brain’s noradrenaline (NA) system, which has been a longtime target for medications to treat attention-deficit/hyperactivity disorder, depression, and anxiety. The study employed what the researchers claim is a groundbreaking methodology, developed to record real-time chemical activity from standard clinical electrodes implanted into the brain routinely for epilepsy monitoring.

The results offer up new insights into brain chemistry, which could have implications for a wide array of medical conditions, and also demonstrate use of the new strategy for acquiring data from the living human brain.

“Our group is describing the first ‘fast’ neurochemistry recorded by voltammetry from conscious humans,” said Read Montague, PhD, the VTC Vernon Mountcastle research professor at Virginia Tech, and director of the Center for Human Neuroscience Research and the Human Neuroimaging Laboratory of the Fralin Biomedical Research Institute at VTC. “This is a big step forward and the methodological approach was implemented completely in humans – after more than 11 years of extensive development.” Montague is senior, and co-corresponding author of the researchers’ published paper in Current Biology, which is titled “Noradrenaline tracks emotional modulation of attention in human amygdala.” In their paper the authors concluded, “By showing that neuromodulator estimates can be obtained from depth electrodes already in standard clinical use in the conscious human brain, our study opens the door to a new area of research on the neuromodulatory basis of human health and disease.”

An international research team led by scientists at the Hudson Institute of Medical Research has found a way to determine which species of gut microbiota are important in certain diseases, and how they interact with other microorganisms to create a healthy microbiome.

The team developed a computational metabolite exchange scoring system to identify microbial cross feeding relationships—the use of metabolites produced by one microorganism as an essential nutrients by another—and how these may be altered in disease. The researchers suggest that understanding such relationships could point to therapeutic approaches for a range of disorders including inflammatory bowel disease, infections, autoimmune diseases and cancer.

“There are roughly 1,000 different bacterial species in a healthy gut—it’s a microscopic multicultural community with over a trillion individual members,” said research lead Samuel Forster, PhD. “Bacteria in our microbiomes exist as communities that rely on each other to produce and share key nutrients between them … We have developed a new computational way to understand these dependencies and their role in shaping our microbiome. This new method unlocks our understanding of the gut microbiome and provides a foundation for new treatment options that selectively remodel microbial communities.”